In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AGL Resources, Inc.

http://www.aglresources.com

Latest From AGL Resources, Inc.

Promore’s Enserpetide Has Phase II Setback In Scar Prevention, Focus Shifts To Ropocamptide

The Swedish firm’s lead program has unexpectedly disappointed in a Phase II scar prevention trial, prompting it to turn its efforts to its only other clinical asset for the treatment of chronic wounds.

Clinical Trials Wound Healing & Tissue Repair

FDA Releases COVID-19 Test Performance Data

The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.

Regulation In Vitro Diagnostics

Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge

Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.

Financing StartUps and SMEs

Tech Transfer Roundup: United Neuroscience Unveils Pair Of Collaborations In CTE, Alzheimer’s

Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.

Deals Research & Development
See All

Company Information

UsernamePublicRestriction

Register